Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

UK’s Cancer Drugs Fund given new lease of life

Government invests £400m and pledges Fund will remain until 2016

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

Novartis day

Novartis’ combo COPD inhaler cleared in EU

Becomes first dual action bronchodilator approved in EU for COPD

- PMLiVE

Pharma firms ramp up Cancer Drugs Fund pressure

Novartis, Roche and Sanofi join forces to highlight public attitudes to medicines access

China flag thumb

Novartis’ Alcon unit diverted trial money for bribes, claims paper

21st Century Business Herald publishes more allegations of corruption in China

- PMLiVE

NICE demands more data for Sanofi’s oral MS drug

UK body won't recommend Aubagio for NHS use based on current information

Harnessing social media for campaign success

Digital excellence from Ruder Finn's meningitis work for Novartis

Novartis building

Novartis signs cell therapy deal with Regenerex

Involves platform that could allow transplant patients to live without lifelong immunosuppression

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

Bayer wins new Eylea approval in Europe

Macular oedema indication will provide more competition for Novartis’ Lucentis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links